Abbott Laboratories (ABT): Brian B Yoor , Senior Vice President and CFO of Abbott Laboratories sold 565 shares on Jun 1, 2016. The Insider selling transaction was reported by the company on Jun 3, 2016 to the Securities and Exchange Commission. The shares were sold at $39.49 per share for a total value of $22,312.41 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 29, 2016, Deepak S. Nath (Senior Vice President) sold 53 shares at $41.31 per share price.On Mar 2, 2016, Robert B Ford (Executive Vice President) sold 1,706 shares at $39.28 per share price.Also, On Mar 2, 2016, Stephen R Fussell (Executive Vice President) sold 1,402 shares at $39.26 per share price.On Mar 2, 2016, Jaime Contreras (Senior Vice President) sold 10,617 shares at $38.94 per share price.
Shares of Abbott Laboratories (ABT) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.35 points or -0.89% at $39.18 with 1,08,41,185 shares getting traded. Post opening the session at $39.52, the shares hit an intraday low of $39.02 and an intraday high of $39.54 and the price vacillated in this range throughout the day. The company has a market cap of $57,561 M and the number of outstanding shares has been calculated to be 1,46,91,52,000 shares. The 52-week high of Abbott Laboratories is $51.74 and the 52-week low is $36.
Company has been under the radar of several Street Analysts.Abbott Laboratories is Reiterated by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 48 from a previous price target of $45 .The Rating was issued on Apr 11, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.